

## FluMist<sup>®</sup> (influenza vaccine live) – Self-administration approval

- On September 20, 2024, the [FDA announced](#) the approval of [AstraZeneca's FluMist \(influenza vaccine live\)](#) intranasal spray, for self- or caregiver-administration.
- FluMist is the first influenza vaccine that does not need to be administered by a healthcare provider.
- FluMist is approved for the prevention of influenza disease caused by influenza virus subtypes A and B in individuals 2 through 49 years of age.
- For those interested in self- or caregiver-administration, AstraZeneca plans to make the vaccine available through a third-party online pharmacy. Those who choose this option will complete a screening and eligibility assessment when they order FluMist. The third-party pharmacy determines eligibility based on the completed screening and, if it is determined that the intended vaccine recipient is eligible, the pharmacy writes the prescription and ships the vaccine to the address provided by the individual who placed the order.
  - The vaccine can then be administered to the prescribed household member(s) at their convenience.
  - A caregiver should administer FluMist to individuals 2 through 17 years of age, as individuals in this age group should not self-administer the vaccine.
  - Vaccine recipients and caregivers who administer FluMist will be sent the vaccine, the Prescribing Information, Information for Patients and their Caregivers and Instructions for Use. The Instructions for Use provides detailed instructions for storage, administration and disposal of FluMist.
- FluMist will also continue to be available in offices and pharmacies for administration by healthcare professionals.
- FluMist for self-administration is expected to be available through an online pharmacy starting Fall 2025.